RemeGen's high P/S ratio, driven by current investor sentiment and future expectations, may be concerning given the company's less than stellar revenue forecasts. Unless conditions improve, these prices may not be reasonable.
Despite RemeGen's subdued revenue growth projections, it trades at a P/S ratio similar to the industry, suggesting investors may be less bearish than analysts. However, its weaker revenue outlook could risk a share price decline and pose a risk to shareholders.
$恒生指數(800000.HK)$plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion. Pharmaceuticals were sold off.$榮昌生物(09995.HK)$once collapsed 27.5% to $22.8; last at $24.9, down 21%. $三葉草生物-B(02197.HK)$nosedived 9.6% to $0.47, hitting record low.$維亞生物(01873.HK)$...
In FT's story, The commerce department is expected to place more than two dozen Chinese companies on the entity list on Thursday, including some involved in biotechnology. The news triggers the sell-off in Hong Kong. $藥明生物(02269.HK)$$藥明康德(02359.HK)$$三葉草生物-B(02197.HK)$$榮昌生物(09995.HK)$
榮昌生物股票討論區
HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off
Pharmaceuticals were sold off. $榮昌生物(09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$三葉草生物-B(02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $維亞生物(01873.HK)$ ...
The news triggers the sell-off in Hong Kong.
$藥明生物(02269.HK)$$藥明康德(02359.HK)$$三葉草生物-B(02197.HK)$$榮昌生物(09995.HK)$
暫無評論